SCHEMBL4048469

SCHEMBL4048469

Fc1cccc(-c2nc3[nH]ncc3cc2-c2ccncn2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.60
ADORA2B P29275 6/20 0.60
ADORA1 P30542 6/20 0.60
EGFR P00533 2/20 0.43
CLK4 Q9HAZ1 2/20 0.40
DCLK1 O15075 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
PRKACA P17612 1/20 0.40
FLT3 P36888 1/20 0.40
FRK P42685 1/20 0.40
MAPK9 P45984 1/20 0.40
CSNK1A1 P48729 1/20 0.40
GSK3B P49841 1/20 0.40
MINK1 Q8N4C8 1/20 0.40
SLK Q9H2G2 1/20 0.40
MAP4K5 Q9Y4K4 1/20 0.40
MAPK14 Q16539 2/20 0.40
MAPK10 P53779 1/20 0.40
ADORA3 P0DMS8 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29894085 0.87 ADORA2A (0.67) ADORA2AADORA2BADORA1EGFRCLK4
SCHEMBL4052237 0.81 ADORA2A (0.44) ADORA2AADORA2BADORA1MAP4K4ADORA3
SCHEMBL14519517 0.79 EGFR (0.63) ADORA2AADORA2BADORA1EGFRCLK4
SCHEMBL5242020 0.77 ADORA1 (0.49) ADORA2AADORA2BADORA1CLK4CCNT1
SCHEMBL4048696 0.75 ADORA2B (1.00) ADORA2AADORA2BADORA1CLK4MAP4K4
SCHEMBL4057421 0.75 GRM5 (0.41) ADORA2AADORA2BADORA1EGFRMAP4K4
SCHEMBL5451980 0.74 MAPK13 (0.42) EGFRCLK4MAP4K4PRKACAFRK
SCHEMBL5240638 0.73 ADORA2B (0.61) ADORA2BADORA1EGFRCLK4MAP4K4
SCHEMBL1445172 0.73 KMO (0.51) CLK4MAP4K4PRKACAGSK3BFYN
SCHEMBL4054512 0.72 ADORA2B (0.59) ADORA2AADORA2BADORA1CLK4MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US claimed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-01-22 US disclosed
EP-1735310-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma, S.A. (ES) 2006-12-27 EP disclosed
WO-2005100353-A1 CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA, SA (ES) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023763-A1 Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA1 ADORA2A 2/4885ADORA2B 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.